Retina Synthesis

147 Folgen

1. Eyes with both Geographic Atrophy and Neovascular AMD: An IRIS Study

   Vom: 12.7.2024
2. The Davio 2 Trial for Neovascular AMD

   Vom: 31.5.2024
3. The GALE Extension Study

   Vom: 17.5.2024
4. AXPAXLI for Diabetic Retinopathy

   Vom: 9.5.2024
5. NSAIDS in the treatment of Central Serous Chorioretinopathy

   Vom: 18.4.2024
6. EY-103 a novel Wnt Pathway Agonist for Treatment of DME and neovascular AMD

   Vom: 4.4.2024
7. Intravitreal Gene Therapy for neovascular AMD with 4D-150

   Vom: 28.3.2024
8. KSI 501 Bispecific Anti-VEGF Biopolymer Treatment of DME

   Vom: 21.3.2024
9. Retinal Vasculitis Following Pegcetcoplan Therapy of Geographic Atrophy

   Vom: 14.3.2024
10. High Dose Aflibercept in Severe Diabetic Macular Edema

    Vom: 7.3.2024
11. IL-6 Inhibition in the Treatment of Uveitis Macular Edema

    Vom: 29.2.2024
12. The High Dose Aflibercept DME Trial

    Vom: 22.2.2024
13. The Annexon Geographic Atrophy Trial

    Vom: 15.2.2024
14. Diagnostics for Retinoblastoma

    Vom: 8.2.2024
15. A Feasbility Evaluating the Use of Home OCT for a Clinical Trial of Faricimab Treatment of nAMD

    Vom: 1.2.2024
16. Visual Outcomes in the Davio Trial Looking at TKI EY-1901

    Vom: 25.1.2024
17. A Post-Hoc Comparison of Syfovre and Izervay in Treatment of Geographic Atrophy

    Vom: 18.1.2024
18. 4 Year Results from DRCR Network Protocol W

    Vom: 11.1.2024
19. Gene Therapy for X-Linked Retinitis Pigmentosa

    Vom: 4.1.2024
20. Optogenetic Therapy of Inherited Retinal Degenerations

    Vom: 21.12.2023